1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424.
2. Bjerregaard JK, Mortensen MB, Pfeiffer P. Trends in cancer of the liver, gall bladder, bile duct, and pancreas in elderly in Denmark, 1980–2012. Acta Oncologica. 2016;55(sup1):40-5.
3. Kabbach G, Assi HA, Bolotin G, Schuster M, Lee HJ, Tadros M. Hepatobiliary Tumors: Update on Diagnosis and Management. J Clin Transl Hepatol. 2015;3(3):169-81.
4. Schoenberg SO, Attenberger UI, Solomon SB, Weissleder R. Developing a Roadmap for Interventional Oncology. The oncologist. 2018;23(10):1162-70.
5. O'Neill SB, O'Connor OJ, Ryan MF, Maher MM. Interventional radiology and the care of the oncology patient. Radiol Res Pract. 2011;2011:160867-.
6. Russo FP, Imondi A, Lynch EN, Farinati F. When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2018;50(7):640-6.
7. Sparchez Z, Mocan T. Contemporary role of liver biopsy in hepatocellular carcinoma. World J Hepatol. 2018;10(7):452-61.
8. Cao XL, Zhenxing; Zhou, Xiang; Geng,Chengyun; Chang,Qing; Zhu, Li; Feng, Wenqi; Xu, Tianyu; Xin, Yujing. Usefulness of real-time contrast-enhanced ultrasound guided coaxial needle biopsy for focal liver lesions. Abdominal Radiology. 2018;44(1):310-7.
9. Mohkam K, Malik Y, Derosas C, Isaac J, Marudanayagam R, Mehrzad H, et al. Percutaneous transhepatic cholangiographic endobiliary forceps biopsy versus endoscopic ultrasound fine needle aspiration for proximal biliary strictures: a single-centre experience. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2017;19(6):530-7.
10. Navaneethan U, Njei B, Lourdusamy V, Konjeti R, Vargo JJ, Parsi MA. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointestinal endoscopy. 2015;81(1):168-76.
11. Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut. 2008;57(11):1592-6.
12. Jain D. Tissue diagnosis of hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4(Suppl 3):S67-S73.
13. De Paepe K, Bonne L, Fotiadis N, Starling N, Chau I, Gerlinger M, et al. Complications and seeding risk after percutaneous liver biopsy in an oncological setting. Journal of Clinical Oncology. 2018;36(4_suppl):246-.
14. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol. 2010;8(10):877-83.
15. Kuo FY, Chen WJ, Lu SN, Wang JH, Eng HL. Fine needle aspiration cytodiagnosis of liver tumors. Acta cytologica. 2004;48(2):142-8.
16. Eggert T, Greten TF. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma. Digestion. 2017;96(1):1-4.
17. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. The Lancet. 2012;379(9822):1245-55.
18. Izzo F, Granata V, Grassi R, Fusco R, Palaia R, Delrio P, et al. Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An Update. The oncologist. 2019.
19. Tian G, Yang S, Yuan J, Threapleton D, Zhao Q, Chen F, et al. Comparative efficacy of treatment strategies for hepatocellular carcinoma: systematic review and network meta-analysis. BMJ Open. 2018;8(10):e021269.
20. She WH, Cheung TT. Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation. Transl Gastroenterol Hepatol. 2016;1:34-.
21. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (London, England). 2002;359(9319):1734-9.
22. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (Baltimore, Md). 2003;37(2):429-42.
23. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (Baltimore, Md). 2002;35(5):1164-71.
24. Young SDS, D; Flanagan, S. Review of the Clinical Evidence for the Use of DEBIRI in the Treatment of Colorectal Metastatic Disease. CardioVascular and Interventional Radiology. 2016;40(4):496-501.
25. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1):41-52.
26. Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. British journal of cancer. 2014;111(2):255-64.
27. Casadei Gardini A, Tamburini E, Iñarrairaegui M, Frassineti GL, Sangro B. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. Onco Targets Ther. 2018;11:7315-21.
28. Sullivan KMY, Raymond S. Minimally invasive therapies for hepatocellular carcinoma: narrowing the gaps. Hepatoma Research. 2018;4(68).
29. Zacharias AJ, Jayakrishnan TT, Rajeev R, Rilling WS, Thomas JP, George B, et al. Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis. PloS one. 2015;10(10):e0139940.
30. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in liver disease. 2010;30(1):52-60.
31. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of hepatology. 2012;56(4):908-43.
32. Young S, Taylor AJ, Sanghvi T. Post Locoregional Therapy Treatment Imaging in Hepatocellular Carcinoma Patients: A Literature-based Review. J Clin Transl Hepatol. 2018;6(2):189-97.
33. Moris D, Vernadakis S, Papalampros A, Vailas M, Dimitrokallis N, Petrou A, et al. Mechanistic insights of rapid liver regeneration after associating liver partition and portal vein ligation for stage hepatectomy. World journal of gastroenterology. 2016;22(33):7613-24.
34. van Lienden KP, van den Esschert JW, de Graaf W, Bipat S, Lameris JS, van Gulik TM, et al. Portal vein embolization before liver resection: a systematic review. Cardiovascular and interventional radiology. 2013;36(1):25-34.
35. van den Bosch MP, W; van der Linden, EM; Meijerink, MR; van Delden, OM; Mali, WP; Reekers, JA;. The radiologist as the treating physician for cancer: interventional oncology. Ned Tijdschr Geneeskd. 2009;153(A 532).
36. Jones SN. Interventional radiology in a palliative care setting. Palliative Medicine. 1995;9(4):319-26.
37. Yee AC, Ho CS. Percutaneous transhepatic biliary drainage: a review. Critical reviews in diagnostic imaging. 1990;30(3):247-79.
38. Nennstiel S, Weber A, Frick G, Haller B, Meining A, Schmid RM, et al. Drainage-related Complications in Percutaneous Transhepatic Biliary Drainage: An Analysis Over 10 Years. Journal of clinical gastroenterology. 2015;49(9):764-70.
39. Madhusudhan KS, Gamanagatti S, Gupta AK. Imaging and interventions in hilar cholangiocarcinoma: A review. World journal of radiology. 2015;7(2):28-44.
40. Pfau PR, Pleskow DK, Banerjee S, Barth BA, Bhat YM, Desilets DJ, et al. Pancreatic and biliary stents. Gastrointestinal endoscopy. 2013;77(3):319-27.
41. Lee SJ, Kim MD, Lee MS, Kim IJ, Park SI, Won JY, et al. Comparison of the efficacy of covered versus uncovered metallic stents in treating inoperable malignant common bile duct obstruction: a randomized trial. Journal of vascular and interventional radiology : JVIR. 2014;25(12):1912-20.
42. Li J, Li T, Sun P, Yu Q, Wang K, Chang W, et al. Covered versus Uncovered Self-Expandable Metal Stents for Managing Malignant Distal Biliary Obstruction: A Meta-Analysis. PloS one. 2016;11(2):e0149066.
43. Penman ID. Coeliac plexus neurolysis. Best Practice & Research Clinical Gastroenterology. 2009;23(5):761-6.
44. Markman JD, Philip A. Interventional Approaches to Pain Management. Medical Clinics of North America. 2007;91(2):271-86.
45. Eisenberg E, Carr DB, Chalmers TC. Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis. Anesthesia and analgesia. 1995;80(2):290-5.
46. Erdek MA, Halpert DE, Fernández MG, Cohen SP. Assessment of Celiac Plexus Block and Neurolysis Outcomes and Technique in the Management of Refractory Visceral Cancer Pain. Pain Medicine. 2010;11(1):92-100.
47. Carroll I. Celiac plexus block for visceral pain. Current pain and headache reports. 2006;10(1):20-5.
48. Wang PJ, Shang MY, Qian Z, Shao CW, Wang JH, Zhao XH. CT-guided percutaneous neurolytic celiac plexus block technique. Abdominal imaging. 2006;31(6):710-8.